Colonic immunity in patients and amoebic liver abscess

Area of Science:

• Immunology
• Gastroenterology
• Infectious Diseases

Background:

• Amoebic liver abscess (ALA) is a severe manifestation of Entamoeba histolytica infection.
• The role of mucosal immunity in amoebiasis, particularly ALA, requires further elucidation.
• Secretory immunoglobulin A (S-IgA) is a key component of mucosal defense.

Purpose of the Study:

• To investigate local mucosal immune responses in patients with amoebic liver abscess (ALA).
• To compare immune parameters between ALA patients, asymptomatic cyst passers, and healthy controls.
• To assess changes in mucosal immunity following antiamoebic therapy.

Main Methods:

• Measurement of fecal S-IgA levels.
• Quantification of antiamoebic antibody titers in feces.
• Assessment of IgA, IgG, and IgM immunocyte counts in rectal mucosa biopsies.
• Study included 13 ALA patients, 10 cyst passers, and 17 healthy controls, with pre- and post-treatment assessments for ALA patients.

Main Results:

• Fecal S-IgA levels and IgA-bearing immunocyte counts were significantly higher in ALA patients and cyst passers compared to healthy controls.
• These elevated levels showed a significant decrease after successful antiamoebic therapy.
• High levels of fecal antiamoebic antibodies were observed in cyst passers and post-treatment ALA cases.

Conclusions:

• Elevated S-IgA and IgA immunocyte counts suggest a local mucosal immune response aimed at controlling Entamoeba histolytica infection.
• The findings highlight the importance of mucosal immunity in the pathogenesis and resolution of amoebiasis.
• Antiamoebic treatment leads to a reduction in these specific immune markers.